Compare · ABT vs ANVS
ABT vs ANVS
Side-by-side comparison of Abbott Laboratories (ABT) and Annovis Bio Inc. (ANVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ANVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $159.07B, about 1434.4x ANVS ($110.9M).
- Over the past year, ABT is down 30.6% and ANVS is up 30.2% - ANVS leads by 60.8 points.
- ABT has been more active in the news (27 items in the past 4 weeks vs 5 for ANVS).
- ABT has more recent analyst coverage (25 ratings vs 4 for ANVS).
- Company
- Abbott Laboratories
- Annovis Bio Inc.
- Price
- $90.77-0.66%
- $1.94+5.15%
- Market cap
- $159.07B
- $110.9M
- 1M return
- -11.56%
- -12.61%
- 1Y return
- -30.56%
- +30.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- AMEX
- IPO
- 2020
- News (4w)
- 27
- 5
- Recent ratings
- 25
- 4
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Annovis Bio Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Latest ABT
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
- Director Starks Daniel J bought $926,537 worth of Common shares without par value (10,000 units at $92.65) and was granted 2,286 units of Common shares without par value, increasing direct ownership by 0.18% to 6,751,103 units (SEC Form 4)
- Director Roman Michael F was granted 2,286 units of Common shares without par value, increasing direct ownership by 27% to 10,764 units (SEC Form 4)
- Director O'Grady Michael was granted 2,286 units of Common shares without par value, increasing direct ownership by 43% to 7,603 units (SEC Form 4)
- Director Mckinstry Nancy was granted 2,286 units of Common shares without par value, increasing direct ownership by 6% to 41,010 units (SEC Form 4)
Latest ANVS
- Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
- Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
- SEC Form 424B5 filed by Annovis Bio Inc.
- Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
- The Credibility Filter Wall Street Uses to Sort Biotech Winners
- SEC Form 4 filed by Hoffman Michael B
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
- Annovis Publishes Historical Review of Buntanetap in The Scientist
- Annovis Bio Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial